F&S reports
Linzagolix for Japanese women with uterine fibroids: a randomized, double-blind, placebo-controlled, phase 3 trial
Par Harada T, Osuga Y, Takahashi H et 3 autres.
Contenu en anglais
Résumé
Objective
To evaluate the efficacy, safety, and pharmacodynamics of linzagolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in patients with heavy menstrual bleeding (HMB) and pain because of uterine fibroids.
Design
Phase 3, multicenter, placebo-controlled, randomized, double-blind, parallel-group, confirmatory study (NCT05445167). Subjects: Premenopausal Japanese women with HMB and moderate-to-severe pain because of uterine fibroids.